StockDocs
Main
Newswire
Learn
Project by
Matthew Castle
Please send feedback to
matthewgcastle@gmail.com
← All companies
GLAX
GSK plc
GLAXF
NYSE
Pharmaceutical Preparations
EDGAR ↗
$23.40
+0.00 0.00%
Key statistics
from XBRL data in SEC filings
Market cap
ⓘ
$101B
Revenue (TTM)
ⓘ
—
Net income (TTM)
ⓘ
—
EPS (TTM)
ⓘ
—
P/E ratio
ⓘ
—
Dividend yield
ⓘ
—
Free cash flow
ⓘ
—
Cash
ⓘ
—
Total assets
ⓘ
—
Gross margin
ⓘ
—
52-week range
ⓘ
$22.50 – $31.48
Recent SEC filings
40 most recent
Annual, quarterly & current reports
6-K
TRANSFER OF TREASURY SHARES
Nov 20, 2026
6-K
VELZATINIB OBTAINS ODD IN JAPAN FOR GIST TREATMENT
Nov 19, 2026
6-K
FDA APPROVES NELKARMI FOR PRETREATED ALK+ NSCLC
Nov 18, 2026
6-K
DIRECTOR/PDMR SHAREHOLDING
Nov 17, 2026
6-K
BEXSERO BOOSTER RECEIVES POSITIVE CHMP OPINION
Nov 13, 2026
6-K
DIRECTOR/PDMR SHAREHOLDING
Nov 12, 2026
6-K
GSK PUBLISHES PROVISIONAL DIVIDEND DATES
Nov 6, 2026
6-K
TOTAL VOTING RIGHTS
Nov 2, 2026
6-K
3RD QUARTER RESULTS
Oct 28, 2026
6-K
RIS-REZ POSITIVE PH 3 OSTEOSARCOMA DATA IN CHINA
Oct 26, 2026
6-K
DIRECTOR/PDMR SHAREHOLDING
Oct 26, 2026
6-K
JEMPERLI DATA SHOW 76% COMPLETE RESPONSE RATE
Oct 26, 2026
6-K
POSITIVE MO-REZ PHASE IB DATA IN OVARIAN CANCER
Oct 26, 2026
6-K
US FDA APPROVES HIBSAGO FOR CHRONIC HEPATITIS B
Oct 21, 2026
6-K
JEMPERLI APPROVED IN MSI-H/DMMR RECTAL CANCER
Oct 19, 2026
6-K
RIS-REZ POSITIVE EARLY DATA IN LUNG CANCER
Oct 19, 2026
6-K
DIRECTOR/PDMR SHAREHOLDING
Oct 15, 2026
6-K
DIRECTOR/PDMR SHAREHOLDING
Oct 14, 2026
6-K
DIRECTOR/PDMR SHAREHOLDING
Oct 13, 2026
6-K
DIRECTOR/PDMR SHAREHOLDING
Oct 13, 2026
6-K
WENDY BECKER CBE - NEW DIRECTORSHIP
Oct 8, 2026
6-K
ADMISSION TO TRADING
Oct 6, 2026
6-K
TOTAL VOTING RIGHTS
Oct 1, 2026
6-K
DIRECTOR/PDMR SHAREHOLDING
Sep 24, 2026
6-K
DIRECTOR/PDMR SHAREHOLDING
Sep 22, 2026
6-K
Sep 15, 2026
6-K
GSK TO ACQUIRE T CELL-ENGAGER FOR MULTIPLE MYELOMA
Sep 15, 2026
6-K
RIS-REZ POSITIVE PH 3 OS LUNG CANCER DATA IN CHINA
Sep 14, 2026
6-K
JIDEYTRO POSITIVE DATA FOR ROS1-POSITIVE NSCLC
Sep 14, 2026
6-K
DIRECTOR/PDMR SHAREHOLDING
Sep 11, 2026
6-K
DIRECTOR/PDMR SHAREHOLDING
Sep 10, 2026
6-K
JAPAN APPROVAL OF SHINGRIX IN A PREFILLED SYRINGE
Sep 10, 2026
6-K
DIRECTOR/PDMR SHAREHOLDING
Sep 9, 2026
6-K
DIRECTOR/PDMR SHAREHOLDING
Sep 9, 2026
6-K
Sep 8, 2026
6-K
TOTAL VOTING RIGHTS
Sep 1, 2026
6-K
MRNA FLU VACCINE CANDIDATE TO ADVANCE TO PHASE III
Sep 1, 2026
6-K
DIRECTOR/PDMR SHAREHOLDING
Aug 26, 2026
6-K
DIRECTOR/PDMR SHAREHOLDING
Aug 24, 2026
6-K
FIRST GLOBAL APPROVAL FOR HIBSAGO IN JAPAN
Aug 24, 2026